REGMF Stock Chart & Stats
$10.95
--
Market closed
$10.95
--
Day’s Range― - ―
52-Week Range$5.06 - $16.02
Previous CloseN/A
VolumeN/A
Average Volume (3M)16.00
Market Cap
$8.89B
Enterprise Value$52.85K
Total Cash (Recent Filing)$2.74B
Total Debt (Recent Filing)$2.09B
Price to Earnings (P/E)54.6
Beta2.61
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.29
Shares Outstanding208,581,240
10 Day Avg. Volume50
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)9.84
Price to Sales (P/S)10.96
P/FCF Ratio-253.57
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.08Price Target Upside46.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.71
Revenue Forecast (FY)$892.22M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRemeGen reported a sharp acceleration in revenue growth (TTM), reflecting strengthening commercial traction for its therapies. Sustained high top-line growth supports scale economics, expands market penetration, and underpins long-term revenue visibility if product adoption and geographic rollouts continue.
High Profitability MarginsThe company delivered robust operating and net margins near ~21.8% in the TTM period with very high gross margins. Persistent high margins indicate pricing power and efficient cost structure, enabling reinvestment in R&D and commercialization and supporting durable cash generation if maintained.
Improved Leverage And ROELeverage has meaningfully improved versus 2024 and equity has grown, while ROE reached ~28%. A stronger capital structure and high ROE indicate more efficient capital use and reduced financing risk, improving financial flexibility for long-term R&D, commercialization and strategic investments.
Bears Say
Weak Cash ConversionOperating cash flow is extremely low relative to reported earnings (OCF/NI ~0.02), signaling that reported profits are not yet translating into durable cash. This weak conversion constrains self-funding capacity, heightens refinancing needs, and raises execution risk for sustaining growth.
Volatile Free Cash FlowFree cash flow has been highly volatile, with deep negatives in prior years and only modestly positive in the TTM. Such swings impede consistent investment in manufacturing and R&D, complicate long-term planning, and increase sensitivity to external funding conditions over the medium term.
Historical Profitability & Capital SwingsThe business has experienced large historical swings in earnings and capital structure, reducing predictability. This episodic volatility implies execution and scaling risks remain, making forward margin and cash-flow forecasts less reliable until consistent performance is established.
RemeGen Co. Ltd. Class H News
REGMF FAQ
What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was $5.06 and its highest was $16.02 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is $8.89B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s upcoming earnings report date is Aug 25, 2026 which is in 31 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Apr 28, 2026. The company reported $0.086 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of $0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in REGMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RemeGen Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.42%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.80%
Trailing 12-Months
Company Description
RemeGen Co. Ltd. Class H
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People’s Republic of China.
REGMF Stock 12 Month Forecast
Average Price Target
$16.08
▲(46.81% Upside)
Akeso, Inc.
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
3.92% Mutual Funds
― Other Institutional Investors
87.99% Public Companies and
Individual Investors